Secondary Progressive Multiple Sclerosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for secondary progressive multiple sclerosis. 15 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
15
Active US patents
59/100
Avg vulnerability
$1.1B
Annual revenue covered

Originators in Secondary Progressive Multiple Sclerosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 15 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating secondary progressive multiple sclerosis. Each bar = one year. Y-axis scaled to peak year (6 patents).

3
28
3
30
3
32
6
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mayzent
SIPONIMOD
 Novartis 15 59 $1.1B 2028-08-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12533340 Mayzent method of use 75 2036-04-23
11944602 Mayzent method of use 75 2036-04-23
11944602 Mayzent method of use 75 2036-04-23
11944602 Mayzent method of use 75 2036-04-23
12533340 Mayzent method of use 75 2036-04-23
12533340 Mayzent method of use 75 2036-04-23
8492441 Mayzent method of use 68 2030-11-30
8492441 Mayzent method of use 68 2030-11-30
8492441 Mayzent method of use 68 2030-11-30
12071402 Mayzent formulation 61 2032-01-05

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7939519 Mayzent composition of matter 17 2028-08-27
7939519 Mayzent composition of matter 17 2028-08-27
7939519 Mayzent composition of matter 17 2028-08-27
12071402 Mayzent formulation 61 2032-01-05
12071402 Mayzent formulation 61 2032-01-05
12071402 Mayzent formulation 61 2032-01-05
8492441 Mayzent method of use 68 2030-11-30
8492441 Mayzent method of use 68 2030-11-30
8492441 Mayzent method of use 68 2030-11-30
11944602 Mayzent method of use 75 2036-04-23

Related